Thermo Fisher Scientific announced that the U.S. Food and Drug Administration (FDA) has cleared the Thermo Scientific B·R·A·H·M·S CgA II KRYPTOR immunoassay, a chromogranin A (CgA) test and automated immunoassay for the assessment of tumor progression in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients.
GEP-NETs are derived from neuroendocrine cells that can form in the pancreas or in other parts of the gastrointestinal tract. Though these tumors are considered rare diseases, recent data from the National Cancer Institute’s Surveillance, Epidemiology and End Results Program shows a significant increase of more than 500% in the incident rate of this disease in the United States over the last three decades.
Using this new test, laboratories and cancer centers can measure the concentration of CgA in human serum, allowing them to track progression of the tumor and present options for evaluating the success of a treatment, the company says. With the FDA-clearance of this assay, customers will now have a commercially available test that can be deployed in a uniform way in laboratories across the country, ultimately helping improve patient management and support better outcomes.
Further reading: Thermo Fisher Scientific Launches Diomni Enterprise Software
“Thermo Fisher is committed to the development of clinical diagnostics solutions that enable healthcare providers to improve patient outcomes,” says Tina Liedtky, president of clinical diagnostics at Thermo Fisher Scientific. “This assay will enable customers to replace manual laboratory developed tests, increase productivity in their labs, and will provide clear guidance on how to interpret results.”
This new assay is designed to run on the Thermo Scientific B·R·A·H·M·S KRYPTOR compact PLUS random-access immunoassay analyzer. Using TRACE technology, based on Nobel Prize winning chemistry, the analyzer can deliver highly accurate and precise results in less than 30 minutes.
Featured image: B·R·A·H·M·S CgA II KRYPTOR. Photo: Thermo Fisher Scientific
